19 Results for "

colony-forming

" in MedChemExpress (MCE) Product Catalog:
Products (19)

19 Results for "colony-forming" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-135775
CAS No.: 627810-06-4
Purity:  99.92%
Research Areas:  

Cancer

BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC50 of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC50 of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telomere length shortening. Anticancer activities .
loading...
    loading...
Cat. No.: HY-161117
CAS No.: 1497439-74-3
Target:  

Acetyl-CoA synthetase

Research Areas:  

Cancer

AD-8007 is a blood-brain barrier-permeable ACSS2 inhibitor with human IC50 of 0.89 μM and Kd of 116.6 μM. AD-8007 reduces colony-forming ability, lipid storage levels and FASN protein expression, and induces cancer cell death. AD-8007 shrinks established tumors, acts synergistically with radiotherapy to inhibit tumor growth, reduces tumor burden, causes no obvious toxicity to normal brain tissue, and prolongs survival. AD-8007 exhibits superior metabolic stability. AD-8007 is applicable to research related to breast cancer brain metastasis .
loading...
    loading...
Cat. No.: HY-128866
CAS No.: 2332841-25-3
Target:  

Bacterial

Research Areas:  

Infection

TBAJ-876 is an orally active diarylquinoline anti-Mycobacterium agent. TBAJ-876 regulates energy metabolism by targeting the c and ε subunits of Mycobacterium tuberculosis F-ATP synthase, exerts bactericidal activity against replicating Mycobacterium tuberculosis, and retains activity against strains carrying the Rv0678 mutation. TBAJ-876 undergoes N-demethylation in vivo to form its major active metabolite TBAJ-876-M3, which has lower lipophilicity and hERG potassium channel binding affinity. TBAJ-876 is well tolerated in BALB/c mice and significantly reduces the colony-forming units of Mycobacterium tuberculosis in the lungs. In addition, TBAJ-876 exhibits inhibitory activity against Mycobacterium abscessus, reduces bacterial loads in the lungs and spleens of infected mice, and shows no antagonistic effect when used in combination with common antibiotics. TBAJ-876 can be used in studies related to tuberculosis and Mycobacterium abscessus pulmonary diseases .
loading...
    loading...
Cat. No.: HY-149347
CAS No.: 3052302-61-8
Target:  

Bacterial

Research Areas:  

Infection

Mtb-IN-3 (compound 10c) is an inhibitor of Mycobacterium tuberculosis (Mtb). Mtb-IN-3 shows selective, potent in vitro antimycobacterial activity without cytotoxicity. Mtb-IN-3 inhibits colony-forming in spleen in the murine tuberculosis model .
loading...
    loading...
Cat. No.: HY-149346
CAS No.: 2861190-30-7
Target:  

Bacterial

Research Areas:  

Infection

Mtb-IN-2 (compound 10c) is an antimicrobial agent against Mycobacterium tuberculosis (Mtb), without cytotoxicity. Mtb-IN-2 significantly decreases colony-forming units (CFU) in spleen of murine tuberculosis models, and distinguishes both drug-sensitive and drug-resistant Mtb H37Rv strains. Mtb-IN-2 affects methionine metabolism but not folate pathway directly.
loading...
    loading...
Cat. No.: HY-149371
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

HDAC6-IN-16 (compound 5c) is a histone deacetylase 6 (HDAC6) inhibitor, based on Quinazolin-4(3H)-One. HDAC6-IN-16 exhibits anticancer effect, inhibits colony-forming. And HDAC6-IN-16 arrests cell cycle at G2 phase and induces apoptosis .
loading...
    loading...
Cat. No.: HY-120376
CAS No.: 1360562-98-6
Target:  

STAT

Research Areas:  

Cancer

XZH-5 inhibits the phosphorylation of STAT3 and results in the induction of apoptosis and reduction of colony forming ability .
loading...
    loading...
Cat. No.: HY-151915
CAS No.: 3012609-63-8
Target:  

ATM/ATR mTOR

Research Areas:  

Cancer

ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC50 of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC50 of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .
loading...
    loading...
Cat. No.: HY-155055
CAS No.: 3049662-97-4
Research Areas:  

Cancer

Antiproliferative agent-26 (compound 4g) is an antiproliferative agent with much broad range of activity targeting Leukemia, CNS, Melanoma, Renal and Breast (at the concentration of 10 μM). Antiproliferative agent-26 inhibits colony forming and arrests cell cycle at G1 phase/S phase at 5 μM and 25 μM, respectively .
loading...
    loading...
Cat. No.: HY-143641
CAS No.: 2401013-08-7
Target:  

Others

Research Areas:  

Cancer

Anticancer agent 25 is an anticancer agent. Anticancer agent 25 can arrest the cell cycle at the G1 phase, and significantly inhibit tumor cell colony forming and migration even at low concentrations. Anticancer agent 25 can significantly induce cytoplasmic vacuolation. Anticancer agent 25 can be used for the study of prostate cancer, breast cancer, and colon cancer .
loading...
    loading...
Cat. No.: HY-155243
CAS No.: 857758-13-5
Target:  

DNA/RNA Synthesis

Research Areas:  

Inflammation/Immunology

12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC50: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research .
loading...
    loading...
Cat. No.: HY-187179
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CDK2-IN-62 is a predicted CDK2 inhibitor. CDK2-IN-62 induces apoptosis in breast cancer cells and reduces their colony-forming ability. CDK2-IN-62 can be used for the research of breast cancer, ovarian cancer and colorectal cancer .
loading...
    loading...
Cat. No.: HY-185344
CAS No.: 2929236-94-0
Synonyms: TRX01
Target:  

NF-κB

Research Areas:  

Cancer

Ratutrelvir is a NF-κB p65 inhibitor. Ratutrelvir blocks the translocation of NF-κB p65 from the cytoplasm to the nucleus, reduces the phosphorylation levels of NF-κB p65 and IκBα, and inhibits the DNA-binding activity of NF-κB p65. Ratutrelvir inhibits the migration and invasion abilities of breast cancer cells, and reduces their viability and colony-forming capacity. Ratutrelvir can be used for the research of luminal A breast cancer .
loading...
    loading...
Cat. No.: HY-180848
CAS No.: 3051861-49-2
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

Bcl-2-IN-24 (Compound 11g) is an efficient and selective Bcl-2 inhibitor with a Kd value of 11.3 μM. Bcl-2-IN-24 exhibits anti-proliferative activity against HCT-116 cells and A549 cells. Bcl-2-IN-24 effectively inhibits the colony-forming ability of tumor cells and induces cell apoptosis. Bcl-2-IN-24 can be used for research on colon cancer and lung cancer .
loading...
    loading...
Cat. No.: HY-181579
Research Areas:  

Cancer

HDAC6-IN-74 is an orally active, selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 0.036 μM. HDAC6-IN-74 induces tumor cell apoptosis, arrests cells at the S phase of the cell cycle, and impairs cell migration, invasion and colony-forming abilities. HDAC6-IN-74 exerts anticancer effects with no obvious toxicity. HDAC6-IN-74 can be used in the research of cancers such as liver cancer .
loading...
    loading...
Cat. No.: HY-182789
Target:  

VEGFR CDK

Research Areas:  

Cancer

VEGFR2-IN-86 is a dual VEGFR2/CDK2 inhibitor, with an IC50 of 0.06 μM against VEGFR2 and an IC50 of 0.78 μM against CDK2. VEGFR2-IN-86 induces G-phase cell cycle arrest, reduces colony-forming ability and tumor cell migration capacity, and exerts antiproliferative activity in cancer cells. VEGFR2-IN-86 can be used for the research of breast cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-183783
Target:  

PROTACs RET STAT ERK Apoptosis

Research Areas:  

Endocrinology Cancer

PROTAC RET Degrader 2 is a RET degrader with a target IC50 of 0.36 nM. PROTAC RET Degrader 2 is mainly composed of RET-IN-34 (HY-183729) and Thalidomide (HY-14658). PROTAC RET Degrader 2 mediates RET degradation via the ubiquitin-proteasome system. PROTAC RET Degrader 2 induces apoptosis, inhibits colony-forming ability, and exhibits antiproliferative activity in cancer cells. PROTAC RET Degrader 2 suppresses tumor growth in xenograft models. PROTAC RET Degrader 2 can be used in research related to medullary thyroid carcinoma, papillary thyroid carcinoma, and RET fusion-positive lung adenocarcinoma .
loading...
    loading...
Cat. No.: HY-184325
Target:  

Bacterial IKK

Research Areas:  

Infection

NDM-622 is a Colistin (HY-113678) adjuvant. NDM-622 weakly inhibits IKKβ with an IC50 of 20.40 μM. NDM-622 reduces the minimum inhibitory concentration of colistin against colistin-highly-resistant Acinetobacter baumannii and Klebsiella pneumoniae. NDM-622 decreases bacterial colony-forming units in a mouse peritonitis model infected with colistin-highly-resistant Klebsiella pneumoniae. NDM-622 does not modify bacterial lipid A, induce reactive oxygen species production, or increase bacterial membrane permeability. NDM-622 can be used in the research of extensively drug-resistant Gram-negative bacterial infections, colistin-resistant Acinetobacter baumannii infections, and Klebsiella pneumoniae infections .
loading...
    loading...
Cat. No.: HY-N20674
CAS No.: 76472-89-4
Chalcomoracin is an orally active anticancer agent. Chalcomoracin exhibits anticancer, antibacterial, and α-glucosidase inhibitory activities, with an IC50 of 14.23 µM against yeast α-glucosidase and an IC50 of 5.5 μM against FabI of Staphylococcus aureus. Chalcomoracin reduces the phosphorylation levels of ERK, JNK, and P38; enhances the phosphorylation level of ERK1/2; regulates the MAPK, mTOR, AKT, and p53 signaling pathways; upregulates the expression of Chop, Bip, PINK1, GRP78, and GADD153; and downregulates the expression of Alix. Chalcomoracin induces apoptosis (apoptosis), endoplasmic reticulum stress (endoplasmic reticulum stress), paraptosis (paraptosis), ROS production, mitophagy (mitophagy), and autophagy (autophagy); it inhibits cancer cell viability, colony-forming ability, migration, invasion, proliferation, tumorigenesis, fatty acid synthesis, S. aureus growth, vitreous-stimulated retinal cell activity, and cell cycle progression at the G0/G1 phase. Chalcomoracin can be used in research related to hepatocellular carcinoma, non-small cell lung cancer, triple-negative breast cancer, prostate cancer, proliferative vitreoretinopathy, pancreatic cancer, diabetes, and bacterial infections .
loading...
    loading...
  • 1